Clinical Lung Cancer

Clinical Lung Cancer is a peer-reviewed medical journal published bimonthly by the CIG Media Group. It was established in 1999. As of May 2012, the editor-in-chief is David R. Gandara.

Gandara is a member of the Board of Directors of the International Association for the Study of Lung Cancer and the Addario Foundation. He has also served as a member of the Board of Directors of the American Society of Clinical Oncology (ASCO) and as secretary-treasurer. He is furthermore a member of professional committees, including the NCI Investigational Drug Steering Committee and the NCI Science Correlates Committee.

Gandara has published more than 225 articles and 10 book chapters, and holds a B.A. from the University of Texas and an M.D. with honors from the University of Texas Medical Branch.

The journal, Clinical Lung Cancer, publishes articles on detection, diagnosis, prevention, and treatment of lung cancer, with emphasis on recent scientific developments in all areas related to lung cancer. Areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.

The journal publishes editorials, original research papers, comprehensive reviews, current treatment reports, case reports, brief communications, current trials, translational medicine pieces, and a “Meeting Highlights” section.

It is indexed in the following databases: Index Medicus/Pubmed, EMBASE (Excerpta Medica), Current Contents/Clinical Medicine, Science Citation Index Expanded, CINAHL, and Chemical Abstracts.

Image Caption: Cover of Clinical Lung Cancer. Credit: Wikipedia

For more information see: